Skip to main content
PolicySpeak
← All files
BD

BECTON DICKINSON

Company · Spain · EU Transparency Register 196359321438-80

1
position filed
in the 326 files tracked
1
legislative file
of 326 tracked
1
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 925 companies & groups on this site, they rank #594 by legislative files engaged — a count of participation, not a measure of influence.

1
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2016
in the register since

Declares membership of

  • MedTech Europe
  • European Alliance for Access to Safe Medicines (EAASM)
  • European Cancer Organization (ECO)
  • Federation of European Academies of Medicine (FEAM)
  • European Patient Safety Foundation (EUPSF)
  • European Sepsis Alliance

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).

Register category
Companies & groups
Registered as
Becton Dickinson (BD)
Head office
New Jersey, Switzerland
EU office
Eysins

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track BECTON in PolicySpeak: request access →

Work at BECTON DICKINSON? so we know who speaks for it.

Follow the file BECTON DICKINSON engages with

One email on Tuesdays when a new position is filed on this file, from BECTON DICKINSON or from anyone else on it. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

BECTON DICKINSON filed 1 position on 17 May 2026, across 1 of the 326 legislative files tracked here, attaching a full position paper 1 time.

What they argued

Health Checks for Cardiovascular diseasesfiled 17 May 2026PDFsource

Timely diagnosis and appropriate management of Peripheral Arterial Disease (PAD) are essential to improve outcomes, including reduced risk of amputation, cardiovascular events, and death, and improved physical function and quality of life.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Is this your organization?

Everything on this page comes from BECTON DICKINSON’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.